| PRECLINICAL | evidence | Urological Complications of Morbid Obesity and the Role of Bariatric Surgery and Glucagon-Like Peptide-1 Receptor Agonists in Their Management: A Systematic Review. | Semaglutide | — | 2026-06-01 |
| PRECLINICAL | evidence | Do GLP-1 Receptor Agonists Sabotage Fat Grafts? : A Scoping Review of GLP-1 Receptor Agonist Effects on Adipocyte Biology and Implications for Autologous Fat Transfer. | Semaglutide | — | 2026-06-01 |
| PRECLINICAL | evidence | GLP-1 RAs in Substance Use Disorders: Emerging Evidence and Future Directions. | Semaglutide | — | 2026-06-01 |
| PRECLINICAL | evidence | Eating Disorders in the GLP-1 Era: A Spotlight on Emerging Clinical Risks, Research Gaps, and Practice Priorities. | Semaglutide | — | 2026-06-01 |
| PRECLINICAL | evidence | In T2D inadequately controlled with metformin, orforglipron reduced HbA(1c) more than oral semaglutide at 52 wk. | Semaglutide | Glycemic control | 2026-06-01 |
| PRECLINICAL | evidence | Uncovering drug-associated risk signals for neovascular age-related macular degeneration: an integrative pharmacovigilance and proteogenomic study. | Semaglutide | — | 2026-06-01 |
| PRECLINICAL | evidence | Steady-state pharmacokinetics of oral semaglutide using semi-mechanistic pharmacokinetic modelling and population simulations. | Semaglutide | — | 2026-06-01 |
| PRECLINICAL | evidence | Patient Experiences With GLP-1 Receptor Agonists. | Semaglutide | — | 2026-06-01 |
| PRECLINICAL | evidence | Cohort Study: Risk of Gallstones and Biliary Complications With Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes. | Semaglutide | Glycemic control | 2026-06-01 |
| PRECLINICAL | evidence | Spinal Implant-Associated Infection in Type 2 and Type 1 Diabetes: Phenotype-Specific Inflammatory Features and Therapeutic Response to Semaglutide. | Semaglutide | — | 2026-06-01 |
| PRECLINICAL | evidence | Efficacy and safety of novel formulation of semaglutide injection: A multicentre, randomized, comparative, active controlled, phase 3 study in comparison with reference biologic in Indian patients with type 2 diabetes mellitus. | Semaglutide | — | 2026-06-01 |
| PRECLINICAL | evidence | Semaglutide-induced lean mass loss: clinical concern or physiological adaptation. | Semaglutide | — | 2026-06-01 |
| PRECLINICAL | evidence | GLP-1 Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Bridging Hepatic and Cardiovascular Outcomes. | Semaglutide | — | 2026-06-01 |
| PRECLINICAL | evidence | Psychosocial Outcomes in Telemedicine and Long-Acting Incretin-Specific Behavioral Intervention. | Semaglutide | — | 2026-06-01 |
| PRECLINICAL | evidence | A cross-species atlas of the dorsal vagal complex reveals neural mediators of the effects of cagrilintide on energy balance. | Semaglutide | Fatigue & energy | 2026-06-01 |
| PRECLINICAL | evidence | Evaluating the Cardiovascular Benefits of Innovator Semaglutide 2.4 mg (Recombinant DNA (r-DNA)) in Patients With Overweight or Obesity: A Critical Review of Current Evidence. | Wegovy | — | 2026-06-01 |
| PRECLINICAL | evidence | Efficacy and Safety of Once-Weekly Semaglutide Versus Basal Insulin and Other GLP-1 Receptor Agonists in Adults With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs: A Systematic Review and Pairwise Meta-Analysis. | Semaglutide | — | 2026-06-01 |
| PRECLINICAL | evidence | Association between semaglutide 2.4 mg and risk of cardiovascular events in people with overweight or obesity without atherosclerotic cardiovascular disease in the real-world: The SCORE - primary prevention study. | Semaglutide | — | 2026-06-01 |
| PRECLINICAL | evidence | Glucagon-Like Peptide-1 Receptor Agonists Across the Heart Failure Spectrum: A Systematic Review and Meta-Analysis. | Semaglutide | — | 2026-06-01 |
| PRECLINICAL | evidence | Glucagon-like peptide-1 receptor agonists and the risk of surgical intervention in idiopathic intracranial hypertension: A propensity-matched cohort study. | Semaglutide | — | 2026-06-01 |
| PRECLINICAL | evidence | Metabolic Dysfunction-Associated Steatotic Liver Disease: Diagnosis and Management. | Semaglutide | Weight & fat loss | 2026-06-01 |
| PRECLINICAL | evidence | Relative Efficacy of Next-Generation Incretin Therapies for Cardio-Renal Protection in Type 2 Diabetes: Evidence From a Network Meta-Analysis. | Semaglutide | Glycemic control | 2026-06-01 |
| PRECLINICAL | evidence | Cardiometabolic Profiles and Treatment Trajectories of GLP-1 Receptor Agonist Users With Obstructive Sleep Apnea: Real-World Evidence From a Large Private Healthcare Cohort in Poland. | Semaglutide | — | 2026-06-01 |
| PRECLINICAL | evidence | CGM-derived postprandial glucose with IcoSema versus other insulin regimens: a post hoc analysis of COMBINE 1 and 3. | Semaglutide | — | 2026-06-01 |
| PRECLINICAL | evidence | Therapeutic targets for metabolic dysfunction-associated steatohepatitis: a personalized approach to disease management. | Semaglutide | Liver health | 2026-06-01 |
| PRECLINICAL | evidence | Ocular complications from glucagon-like peptide-1 receptor agonists: Clinical evidence, potential mechanisms, and clinical recommendations. | Semaglutide | Glycemic control | 2026-06-01 |
| PRECLINICAL | evidence | Joint TOS/OMA/OAC expert guidance statement on the pharmacological management of United States adults with overweight or obesity using the GRADE approach. | Semaglutide | — | 2026-06-01 |
| PRECLINICAL | evidence | Weight-loss dynamics with tirzepatide versus semaglutide. | Semaglutide | — | 2026-06-01 |
| PRECLINICAL | evidence | GLP-1 Receptor/Dual Agonists for Weight Loss: A Systematic Review and Network Meta-Analysis of RCTs. | Semaglutide | Weight & fat loss | 2026-06-01 |
| PRECLINICAL | evidence | Interpreting Post-Discontinuation Trajectories After Semaglutide or Tirzepatide. | Semaglutide | — | 2026-06-01 |
| PRECLINICAL | evidence | Use of Oral Semaglutide and Associated Clinical Outcomes in Thai Patients With Type 2 Diabetes: Real-World Evidence From the REALISED Study. | Semaglutide | Glycemic control | 2026-06-01 |
| PRECLINICAL | evidence | Factors influencing patient preferences for obesity pharmacotherapy: The triangulation of semi-structured interviews, photovoice study and focus group discussions. | Semaglutide | — | 2026-06-01 |
| PRECLINICAL | evidence | Safety of GLP-1 and Dual GLP-1/GIP Receptor Agonists in Preconception, Pregnancy, and Lactation: A Systematic Review of Maternal, Fetal, and Neonatal Outcomes. | Semaglutide | — | 2026-06-01 |
| PRECLINICAL | evidence | Lower Risk of Cardiovascular Events in Patients With Clinical Atherosclerotic Cardiovascular Disease Who Initiated Semaglutide 2.4 mg in the Real-World: Results From the SCORE-Clinical ASCVD Study. | Semaglutide | — | 2026-06-01 |
| PRECLINICAL | evidence | Real-World Cardiovascular Outcomes of Obesity Treatment With Tirzepatide Versus Semaglutide in Non-Diabetic Adults. | Semaglutide | Weight & fat loss | 2026-06-01 |
| PRECLINICAL | evidence | Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression. | Semaglutide | Weight & fat loss | 2026-06-01 |
| PRECLINICAL | evidence | Safety of Semaglutide After Dialysis Initiation: An Individual-Level Pooled Analysis. | Semaglutide | Glycemic control | 2026-06-01 |
| PRECLINICAL | evidence | Corrigendum to "Efficacy and safety of semaglutide injection in comparison with reference semaglutide for chronic weight management in Indian adults with obesity: A phase III randomized non-inferiority trial" [Metabol Open 30 (2026) 100460]. | Semaglutide | — | 2026-06-01 |
| PRECLINICAL | evidence | Impact of Semaglutide on Hippocampal Injury in a Streptozotocin-Induced Model of Alzheimer's Disease. | Semaglutide | — | 2026-05-31 |
| PRECLINICAL | evidence | Incretin-Based Drugs for Obesity: Common and Drug-Specific Reporting Patterns of Adverse Drug Reactions-A Comparative Disproportionality Analysis Using EudraVigilance Reports Integrating SmPC Data. | Semaglutide | — | 2026-05-31 |
| PRECLINICAL | evidence | GLP-1RA- and Incretin-Based Therapies Within Lifestyle Interventions for Adults with Overweight or Obesity: A Systematic Review and Meta-Analysis. | Semaglutide | Weight & fat loss | 2026-05-31 |
| PRECLINICAL | evidence | Semaglutide use in patients undergoing atrial fibrillation ablation and recurrent arrhythmia: A focused time-to-event meta-analysis. | Semaglutide | — | 2026-05-30 |
| PRECLINICAL | evidence | Retrospective Assessment of Food Noise Changes After Initiation of Injectable Semaglutide for Weight Management in the USA: The INFORM Survey. | Semaglutide | — | 2026-05-30 |
| PRECLINICAL | evidence | The impact of adjuvant anti-obesity medications on 10-year weight loss outcomes after sleeve gastrectomy. | Semaglutide | — | 2026-05-30 |
| PRECLINICAL | evidence | Semaglutide for Alzheimer's disease after evoke and evoke. | Semaglutide | — | 2026-05-30 |
| PRECLINICAL | evidence | Akkermansia muciniphila and GLP-1-Based Therapies: Bidirectional Interactions and Implications for Type 2 Diabetes and MASLD/MASH. | Semaglutide | — | 2026-05-29 |
| PRECLINICAL | evidence | Formulation Engineering of Oral Semaglutide Tablets: Unleashing Gastric Intestinal Permeation with Sodium Caprate. | Rybelsus | — | 2026-05-29 |
| PRECLINICAL | evidence | The Effects of New Antidiabetic Drugs on the Course of Peripheral Arterial Occlusive Disease. | Semaglutide | — | 2026-05-29 |
| PRECLINICAL | evidence | Semaglutide in non-diabetic obese Chinese patients with acute coronary syndrome: a multicenter retrospective study. | Semaglutide | — | 2026-05-29 |
| PRECLINICAL | evidence | GLP-1 receptor agonists for weight management and potential thromboembolic risk reduction in high risk population with cancer, diabetes, cardiovascular disease: A systematic review. | Semaglutide | — | 2026-05-29 |